Skip to content

A Single-Center, Prospective, Single-Arm Exploratory Study of Deep Cervical Lymphovenous Anastomosis to Improve Clinical Symptoms in Patients with Progressive Supranuclear Palsy

A Single-Center, Prospective, Single-Arm Exploratory Study of Deep Cervical Lymphovenous Anastomosis to Improve Clinical Symptoms in Patients with Progressive Supranuclear Palsy

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099383
Enrollment
Unknown
Registered
2025-03-24
Start date
2025-03-24
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progressive Supranuclear Palsy

Interventions

Sponsors

Zhengzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Based on the current Movement Disorder Society (MDS) diagnostic criteria for progressive supranuclear palsy (PSP) (2017) and the Chinese clinical diagnostic criteria for PSP (2016), patients must meet the criteria for clinically confirmed PSP-Richardson syndrome (PSP-RS) or probable PSP-RS. 2.ge between 40 and 75 years. 3.Presence of PSP-RS clinical symptoms for at least 5 years. 4.Ability to walk independently for at least 5 steps. 5.Willingness to participate in the study and provide written informed consent. 6.Stable dosage of symptomatic treatment for PSP within 60 days prior to study initiation..

Exclusion criteria

Exclusion criteria: 1.Atypical variants of progressive supranuclear palsy (PSP). 2.PSP-Richardson syndrome (PSP-RS) patients unable to walk independently for at least 5 steps. 3.Severe cognitive impairment preventing compliance with study procedures. 4.Comorbid neurological or psychiatric disorders (e.g., schizophrenia, severe depression, bipolar disorder) or severe systemic diseases (e.g., acute coronary syndrome, acute heart failure, respiratory failure, severe hepatic or renal dysfunction, uncontrolled hyperthyroidism, poorly controlled rheumatic or autoimmune diseases). 5.Presence of metallic implants or pacemakers contraindicating cranial MRI examination. 6.Unstable general condition, vital signs, or uncontrolled seizures within one week prior to study initiation. 7.Pregnant, planning to conceive, or lactating women. 8.Unwillingness to comply with assessments and study procedures.

Design outcomes

Primary

MeasureTime frame
Progressive Supranuclear Palsy Rating Scale(PSPRS) score;Changes in hematological inflammatory markers;

Secondary

MeasureTime frame
Unified Parkinson's disease rating scale (UPDRS)-? score;Tinetti Balance and Gait Analysis score;Sematic Verbal Fluency score;Phonologic Verbal Fluency score;Schwab and England Activities of Daily Living Scale score;Clinical Global Impression score; Changes in brain lymphatic system imaging indices relative to baseline;

Countries

China

Contacts

Public ContactYang Gaiqing

Zhengzhou Central Hospital

zxyyygq@163.com+86 138 3833 2895

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026